What are CJC-1295 and Ipamorelin?
CJC-1295 and Ipamorelin are two synthetic peptides extensively studied in growth hormone research literature. They are often examined together because they target complementary receptors in the growth hormone signaling pathway, and combination protocols are common in published research.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been modified for extended stability. Ipamorelin is a selective growth hormone secretagogue (GHS) that mimics the activity of ghrelin at a specific receptor. Together, they represent two of the most studied synthetic peptides in the broader category of "growth hormone-releasing peptides" or GHRPs.
This article is intended as a scientific overview for laboratory researchers. All compounds discussed are sold strictly for in-vitro research and are not for human consumption.
Background: The Growth Hormone Axis
Before discussing the individual compounds, a brief review of the growth hormone signaling pathway is useful:
- Growth hormone-releasing hormone (GHRH) is produced by the hypothalamus and travels to the pituitary gland
- GHRH binds the GHRH receptor on pituitary somatotroph cells, signaling them to release growth hormone
- Ghrelin (a peptide hormone produced primarily in the stomach) binds the growth hormone secretagogue receptor (GHSR), also on somatotroph cells, providing a separate signal for growth hormone release
- Both signals can act synergistically — when both GHRH and ghrelin are present, growth hormone release is greater than the sum of individual effects
CJC-1295 mimics the GHRH signal. Ipamorelin mimics the ghrelin signal. The "synergistic" effect of these two pathways together is the rationale for studying them in combination.
CJC-1295: A Modified GHRH Analog
Background
Native GHRH has a short biological half-life (just a few minutes) due to rapid enzymatic degradation, particularly by an enzyme called dipeptidyl peptidase-4 (DPP-4). This makes natural GHRH impractical for sustained research applications.
CJC-1295 was developed as a modified GHRH analog with amino acid substitutions that resist DPP-4 degradation, dramatically extending its stability. There are two related forms in the research literature:
- CJC-1295 (without DAC) — also called Modified GRF (1-29). Half-life of approximately 30 minutes, similar to other GHRH analogs
- CJC-1295 with DAC — includes a "drug affinity complex" linker that binds to serum albumin, dramatically extending half-life to multiple days
The two forms are sometimes confused but have very different pharmacokinetic profiles in research models.
Proposed Mechanism
CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, mimicking the action of natural GHRH. This binding activates downstream signaling cascades (including cAMP and protein kinase A pathways) that result in growth hormone release in animal models. The amino acid modifications resist DPP-4 cleavage, so the compound remains active much longer than native GHRH.
Ipamorelin: A Selective GHRP
Background
Ipamorelin belongs to the class of compounds known as growth hormone secretagogues (GHS) or, more specifically, growth hormone-releasing peptides (GHRPs). Unlike CJC-1295, Ipamorelin acts at a different receptor entirely — the growth hormone secretagogue receptor (GHSR), which is the same receptor that binds the natural hormone ghrelin.
Ipamorelin was specifically designed to be a selective GHSR agonist. Earlier compounds in the GHRP class (like GHRP-2 and GHRP-6) also activate the GHSR, but they additionally cause secondary effects on cortisol, prolactin, and appetite. Ipamorelin's selectivity profile is one of the reasons it became a popular research compound — it produces growth hormone-related effects in animal models with minimal off-target activity.
Proposed Mechanism
Ipamorelin binds the GHSR (also called GHS-R1a) on pituitary somatotroph cells. This receptor activation triggers calcium signaling and phospholipase C activity, which in turn promotes growth hormone release. Because Ipamorelin's selectivity favors the GHSR over other related receptors, it produces a cleaner research profile compared to less selective compounds in the same class.
Why They're Studied Together
The pituitary somatotroph cell has both GHRH receptors and GHSRs on its surface. When only one signaling pathway is activated, the growth hormone response is moderate. But when both pathways are activated simultaneously, the response is significantly larger than additive — a phenomenon called synergistic potentiation.
This is the rationale for studying CJC-1295 and Ipamorelin in combination: each compound activates one pathway, and together they produce a stronger response in animal models than either alone. Combination protocols have been examined in research literature for various models of growth hormone deficiency, body composition, and tissue research.
Current Research Areas
The published literature on these peptides spans several research interest areas. The following list represents research interest areas in the published literature — not validated therapeutic uses.
- Growth hormone deficiency models: Animal studies examining pituitary response in models of impaired GH signaling
- Body composition research: Effects on lean mass and adipose tissue in rodent models
- Bone mineral density studies: Animal models examining osteoblast activity and bone matrix
- Aging research: Studies of GH axis changes in aging animal models
- Metabolic research: Effects on glucose handling and lipid metabolism in laboratory models
- Pharmacokinetic studies: Comparing CJC-1295 with vs. without DAC for research utility
Researchers can find primary literature via PubMed searches for "CJC-1295" or "Ipamorelin".
It's important to note that despite the volume of preclinical interest, neither CJC-1295 nor Ipamorelin has received FDA approval or any major regulatory approval for therapeutic use in humans. They remain research compounds.
Stability and Laboratory Handling
Both peptides are typically supplied as lyophilized powders. They share many handling considerations with other research peptides, with a few specific notes.
General Handling Considerations
- Lyophilized form storage: Refrigerated at 2-8°C is acceptable for short-term storage; frozen at -20°C is recommended for long-term storage
- Reconstitution: Bacteriostatic water for injection (BWFI) is the standard solvent. See our peptide reconstitution guide for full step-by-step technique
- Reconstituted shelf-life: Generally stable for 2-4 weeks under refrigeration. Avoid repeated freeze-thaw cycles which degrade peptide integrity
- Light sensitivity: Standard precautions — protect reconstituted solutions from prolonged light exposure
- Not for combination in same vial: If using both compounds in research, they should be reconstituted separately and kept in separate vials. Combining lyophilized peptides into a single vial complicates accurate dosing and stability tracking
Verifying Quality
Research-grade CJC-1295 and Ipamorelin should ship with batch-specific Certificates of Analysis documenting:
- Purity by HPLC (greater than 99% is the industry research standard)
- Identity confirmation by mass spectrometry
- For CJC-1295 with DAC, additional verification of the drug affinity complex
For more on how peptide quality is verified analytically, see our guide on HPLC and Mass Spectrometry.
View our published third-party COAs for examples of proper documentation.
Frequently Asked Research Questions
What's the difference between CJC-1295 with DAC and without DAC?
The "DAC" stands for "drug affinity complex" — a chemical linker that binds to serum albumin in animal models. CJC-1295 with DAC has a much longer half-life (several days) compared to CJC-1295 without DAC (about 30 minutes). For research purposes, the two forms are different compounds with very different pharmacokinetic profiles. Studies examining "CJC-1295" should specify which form was used.
Can CJC-1295 and Ipamorelin be used in the same research protocol?
The published literature has examined both individual and combination protocols. Combination studies have reported synergistic effects on growth hormone release in animal models due to the activation of two complementary receptors. Specific protocols depend entirely on the research question being investigated.
Why is Ipamorelin called "selective"?
Ipamorelin selectively activates the growth hormone secretagogue receptor (GHSR) without significantly activating other related receptors that affect cortisol, prolactin, and appetite. This selectivity distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6, which produce broader effects in research models. The selectivity makes Ipamorelin useful for studying GH-axis activity specifically, with less confounding from off-target signaling.
Are these peptides approved for human use?
No. Neither CJC-1295 nor Ipamorelin has been approved by the FDA or any major regulatory body for therapeutic use. Both remain research compounds. Materials sold by Prime Peptide Solutions are explicitly for laboratory research only and not for human consumption.
What purity should research-grade CJC-1295 and Ipamorelin have?
Both should be characterized at greater than 99% purity by HPLC, with identity confirmed by mass spectrometry. The COA should document batch-specific values rather than only stating minimum specifications. CJC-1295 with DAC requires additional verification of the drug affinity complex due to its more complex structure.
Conclusion
CJC-1295 and Ipamorelin are among the most extensively studied synthetic peptides in growth hormone research literature. Their complementary mechanisms — CJC-1295 acting at the GHRH receptor and Ipamorelin acting at the GHSR — provide a useful research framework for examining the growth hormone signaling axis. Combination protocols leverage the synergistic activity of these two pathways for stronger effects in animal models compared to either compound alone.
Despite the breadth of preclinical research, both compounds remain research-only. For researchers working with these peptides, sourcing from suppliers who provide third-party verified Certificates of Analysis is essential for experimental reproducibility.
Disclaimer: This article is provided for educational and research purposes only. Information contained herein is a summary of publicly available scientific literature and does not constitute medical advice. CJC-1295, Ipamorelin, and all peptide compounds sold by Prime Peptide Solutions are intended strictly for laboratory research and are not for human consumption, in-vivo human use, or therapeutic application. Researchers are responsible for compliance with all applicable regulations governing peptide use in their jurisdiction.
References & Further Reading
- PubMed: Current peer-reviewed CJC-1295 literature
- PubMed: Current peer-reviewed Ipamorelin literature
- Related: BPC-157 Mechanism of Action
- Related: Understanding HPLC and Mass Spec
- Related: Peptide Reconstitution Guide
- For COAs and product specifications, see our published Certificates of Analysis